Asset
SER-287
Seres Therapeutics Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03759041 | phase2 | terminated | 2018-12-19 | 2021-05-28 | Seres Therapeutics, Inc. | A Study to Assess Efficacy and Safety of SER-287 in Adults With Active Mild-to-Moderate Ulcerative Colitis |
| NCT02618187 | phase1 | completed | 2016-01-13 | 2017-12-06 | Seres Therapeutics, Inc. | A Study to Evaluate the Safety, Tolerability and Microbiome Dynamics of SER-287 in Subjects With Mild-to-Moderate Ulcerative Colitis |
FDA applications (0)
This company has no applications containing this asset.